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Defects in telomere maintenance can result in telomere fusions that likely play a causative role in carcinogenesis by
promoting genomic instability. However, this proposition remains to be fully understood in human colon
carcinogenesis. In the present study, the temporal sequence of telomere dysfunction dynamics was delineated by
analyzing telomere fusion, telomere length, telomerase activity, hotspot mutations in KRAS or BRAF, and TP53 of
tissue samples obtained from 18 colon cancer patients. Our results revealed that both the deficiency of p53 and the
shortening ofmean telomere lengthwere not necessary for producing telomere fusions in colon tissue. In five cases,
telomere fusion was observed even in tissue adjacent to cancerous lesions, suggesting that genomic instability is
initiated in pathologically non-cancerous lesions. The extent of mean telomere attrition increased with lymph node
invasiveness of tumors, implying that mean telomere shortening correlates with colon cancer progression.
Telomerase activity was relatively higher in most cancer tissues containingmutation(s) in KRAS or BRAF and/or TP53
compared to those without these hotspot mutations, suggesting that telomerase could become fully active at the
late stage of colon cancer development. Interestingly, the majority of telomere fusion junctions in colon cancer
appeared to be a chromatid-type containing chromosome 7q or 12q. In sum, this meticulous correlative study not
only highlights the concept that telomere fusion is present in the early stages of cancer regardless of TP53/KRAS
mutation status, mean telomere length, and telomerase activity, but also provides additional insights targeting key
telomere fusion junctions which may have significant implications for colon cancer diagnoses.
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Telomeres are repetitive structures at the end of chromosomes that are
essential for maintaining and protecting the chromosomes from
degradation and end-to-end fusion [1,2]. Many studies suggest that
the loss of telomere function leads to genomic instability [3–7].
Telomere dysfunction could be produced by critical telomere erosion,
by disruption of various telomere-capping proteins, by stalling telomere
replication, by epigenetic changes in subtelomeres, or by prolonged
mitotic arrest [8–13]. The production of a broken chromosome with
the dysfunctional telomere is mutagenic, because fusion of these
dysfunctional telomeres propagates a breakage-fusion-bridge cycle
during mitosis that results in chromosome rearrangements, deletions
or amplifications. Thus, telomere dysfunction is likely a key event
initiating genomic instability leading to cancer formation. Telomere
integrity is mediated in part by the reverse transcriptase telomerase,which adds telomeric DNA repeats de novo at the ends of chromosomes
([14,15]). In human cells, telomerase activity has been shown to be very
low or absent in non-malignant somatic cells. In contrast, it is activated
in stem cells, germ cells, and nearly 90% of human cancer cells.
Collectively, these observations imply that the immortality conferred by
telomerase plays a key role in cancer development [16–18]. Telomerase
is therefore required for the infinite proliferation of almost all cancer
cells [19].
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telomeres (from telomerase deficiency) along with the incomplete p53-
dependent DNA damage response pathway (from p53 deficiency) lead
to increased chromosome end-to-end fusions, resulting in the massive
genomic instability necessary for cancer initiation [20,21]. Telomere
dysfunction can also be considered as a barrier to cancer development in
the presence of intact p53-cell cycle checkpoint response [22].
Therefore, these data suggest that telomere dysfunction plays a dual
role in carcinogenesis. Recent murine studies also provide evidence that
telomere dysfunction (induced either by telomerase deficiency or ectopic
expression of dominant-negative trf2) promotes chromosomal instability
that drives the early stage of carcinogenesis, and subsequent telomerase
activation is critical to cancer progression including metastasis [23,24].
Although murine telomerase-knockout models have been significantly
useful in identifying and characterizing the major basic biology of
telomeres and telomerase, it is important to note that there are several
fundamental differences between laboratory mice and humans in
telomere biology [25–27]. For example, laboratory mice have about
more than four-fold longer telomere length but a 40-fold shorter life-
span than humans. Telomerase is expressed in almost all organs of mice,
while absent or not detectable in most organs of humans. In addition,
only p53 function is required for the replicative arrest of murine cells but
inactivation of both the p53 and p16 pathways are needed for human
cells to become malignant [28,29]. There are obviously environmental
differences between human life in the world and murine life in the
animal facility cage. Thus, it is critical to study carefully the complexity
of human carcinogenesis by contrasting the distinctive features of
telomerase and telomere biology in mouse and human carcinogenesis.
Human colorectal carcinogenesis is a well-characterized disease
model for identifying genetic disposition of cancer pathogenesis [30].
Approximately 85% of colorectal cancers are characterized by a
chromosome instability (CIN) phenotype, which displays an
increased frequency of structural and numerical chromosomal
changes. It is thought that KRAS (not BRAF) and TP53 gene
mutations are linked to the CIN-associated carcinogenesis [31–34]. A
number of studies have reported that accelerated telomere shortening is
observed in colorectal cancer lesions when compared to adjacent non-Table 1. Patient Characteristics.
Case No. Age Sex TMN Stage
1012–35 67 F TisMxN0 0
811–15 88 M T1MxN0 I
1105–08 50 M T3MxN0 IIB
1010–39 55 F T3MxN0 IIB
1005–69 67 M T3MxN0 IIB
1008–15 80 F T3MxN0 IIB
807–54 89 F T3M0N0 IIB
1012–31 89 M T3MxN0 IIB
903–22 78 M T4MxN0 IIB
1106–29 54 M T4bMxN0 IIB
1005–62 60 M T3MxN1 IIIB
609–08 65 F T3MxN1 IIIB
114–30 65 M T3MxN1b IIIA
908–41 65 F T4MxN1 IIIB
708–50 70 M T3M1N1 IIIB
910–44 47 M T3MxN2 IIIC
1004–70 68 F T3MxN2 IIIC
808–41 60 M T4MxN2 IIIC
Group above dashed line indicates lymph node non-invasive cases.
a QC, histologic quality control assessment of tissue samples.cancerous lesions [35–37]. While telomere shortening seems to be
involved in the process of cancer progression, it remains unclear whether
or when these short telomeres actually become dysfunctional.
Interestingly, a recent study shows that extensive telomere erosion is
associated with large-scale chromosome rearrangements in polyps
obtained from familial adenomatous polyposis patients with APC gene
defects. These data propose that the combination of short telomeres
together with APC gene alterations in polyps may lead to chromosome
instability, potentially driving clonal evolution and colorectal cancer
progression [38]. Nonetheless, it is apparent that telomere length is not
the sole factor determining the fusogenic behavior of human telomeres
in cells, but other biological and physiological changes also cause the
telomere fusion event [12,39–46]. There is a lack of conclusive data as
to the degree and nature of telomere dysfunction that is linked to
human colorectal cancer.
Telomere fusion (or association) has traditionally been detected by
cytogenetic analysis using a significant amount of proliferating cells to
obtain metaphase chromosomes, making it difficult to study kinetics
and pathogenetic significance of telomere fusion events in large
cohorts, especially in tissue samples. Alternatively, the anaphase
bridge index is often measured in tissue sections as a surrogate marker
of telomere dysfunction. It has been reported that there are 15% to
20% of anaphase bridges in tissue sections ranging from high-grade
dysplasia to colon cancer, while there are less than 1% of anaphase
bridges in adenoma [47]. However, a temporal relationship between
telomere dysfunction dynamics and the known genomic and
phenotypic characteristics of human colorectal cancer development
has not yet been fully established. It is also known that the formation of
anaphase bridges is associated with other events, such as cohesin defects
[48] or internal double-strand DNA breaks [49]. Therefore, to
overcome these technical difficulties of detecting and analyzing telomere
fusions directly within human solid tumor tissue, we have developed a
new molecular technique (called Telomere-Associated Repeat fusion
PCR “TAR-fusion PCR” assay [50]). This assay indeed detected
telomere fusions in early breast cancer such as ductal carcinoma in situ
(DCIS), providing strong evidence for the occurrence of telomere
dysfunction during breast cancer development [50].Differentiation Location QCa (% tumor)
Moderately Sigmoid 80
Moderately Ascending 100
60
Moderately Ascending 80
Poorly Sigmoid 70
70
Moderately Sigmoid 70
50
Moderately 70
Moderately to poorly 60
Poorly 50
Moderately 65
Cecum 80
Poorly 55
Poorly Cecum 60
Moderately Sigmoid 60
Moderately 60
Well–differenced 70
Table 2. Primer Sequences.
Name Sequences (5′ to 3′)
Gene mutation analysis
TP53_exon 5-6_forward cacttgtgccctgactttca
TP53_exon 5-6_reversed ggcccttagcctcgtaagc
TP53_exon 5 for seq aaccagccctgtcgtctct
TP53_exon 6 for seq agagacgacagggctggtt
TP53_exon 7-8_forward ctgcttgccacaggtctcc
TP53_exon 7-8_ reversed taactgcacccttggtctcc
TP53_exon 7 for seq tggaagaaatcggtaagaggtg
TP53_exon 8 for seq gcttcttgtcctgcttgctt
KRAS_c.12/13_forward cgtctgcagtcaactggaat
KRAS_ c.12/13_reversed ccctgacatactcccaagga
KRAS_c.12/13 for seq gtatcaaagaatggtcctgc
KRAS_c.61_forward tcatctttggagcaggaaca
KRAS_ c.61_reversed cactgctctaatcccccaag
KRAS_c.61 for seq ggtgcactgtaataatccag
BRAF_V600E_forward ggaaagcatctcacctcatcc
BRAF_V600E_ reversed gaacactgatttttgtgaatactgg
BRAF_V600E for seq catttcaagccccaaaaatct
Telomere qPCR
Ref_1_forward ggtgatgggatttccattgatg
Ref_1_reversed cttcattgacctcaactacatgg
Ref_2_forward gggaagctcactggcatgg
Ref_2_reversed ttcttgatgtcatcatatttggcagg
Telg a acactaaggtttgggtttgggtttgggtttgggttagtgt
Telc a tgttaggtatccctatccctatccctatccctatccctaaca
HBG1 b gcttctgacacaactgtgttcactagc
HBG2 b caccaacttcatccacgttcacc
36B4u b cagcaagtgggaaggtgtaatcc
36B4d b cccattctatcatcaacgggtacaa
a [16].
b [15].
816 Telomere fusion in colon cancer Tanaka et al. Neoplasia Vol. 16, No. 10, 2014In this present study, we investigated the relationship between
known genetic alterations and the dynamic of telomere dysfunction in
human colon cancer tissues and adjacent non-cancerous tissues by
determining telomere fusion, telomere length, and telomerase activity.
These correlative studies demonstrate that a majority of colon cancerTable 3. Summary of Mutations and Telomere Dysfunction Dynamics.
Case No. TP53Exon 5–8 
KRAS
Codons 12&13a
BRAF
V600E
Telome
Tumor  
1012–35 7q–7q
811–15 GtTGGC other
1105–08 Codon 245 (GGC>AGC) GtTGGC
1010–39 Codon 132 (AAG>AGG) aGTGGC other
1005–69 7q–7q
1008–15 +
807–54 Codon 199 (GGA>AGA) + 7q–7q
1012–31 Codon 162 (ATC>AAC) 7q–7q, 4p
903–22 + other
1106–29 4pq–XpY
1005–62 7q–7q, oth
609–08 + 7q–7q
1104–30 GtTGGC other
908–41 Codon 131 (AAC>GAC) + 4pq–XpY
708–50 +
910–44 Codon 282 (CCG>CTG) 7q–7q, 4p
1004–70 Codon 135 (TGC>TGG) GGTGaC 7q–7q
808–41 7q–7q
Group above dashed line indicates lymph node non-invasive cases.
a Mutation shown in lower case. There were no mutations found in codon 61.
b 7q-7q and 4pq-XpYp indicate a fusion junction containing DNA sequences shown in Figure 4, A and B, re
Identical fusion junctions between paired cancer and adjacent DNA samples were shown in italic.
c Graph is shown in Figure 2C.
d Graph is shown in Figure 3C.specimens have telomere fusion regardless of the status of hotspot
mutations in both TP53 and KRAS genes. Mean telomere shortening
and weak telomerase activity were not associated strongly with the
presence of telomere fusion, implying that telomere fusion is a key
genetic aberration resulting from telomere dysfunction. Moreover, the
results from the telomere fusion junction analyses suggest that the
nature of telomere fusion junctions may be linked to neoplasticity.
Materials and Methods
Tissue Samples
Tissues specimens were obtained at the time of surgery, immediately
frozen in liquid nitrogen, and stored in liquid nitrogen until use. All
patients had only surgery without combination therapies. Paired frozen
tissues (100–150 mg) from sporadic colon cancer tissues (n = 18) and
their adjacent tissues (n = 18) were obtained from the tissue bank at the
Indiana University Simon Cancer Center. All cases were reviewed
by pathologists to assess tumor histology. Each pathologically
normal adjacent tissue was harvested at least 2 cm distal from the
cancer tissue. The purity of each specimen was shown as % tumor
in Table 1. The study was approved by the institutional review
board of the Indiana University.
DNA Isolation
Genomic DNA from each frozen tissue was isolated by a salt
precipitation method as previously described [51]. Briefly, about
20 mg of each frozen tissue fragment was minced quickly in cold
PBS (−) and the PBS (−) was removed by centrifuging at 3500× g.
The pellets were resolved in lysis buffer (20 mM Tri-HCl/pH 8.2,
10 mM EDTA, 400 mMNaCl, 0.5% SDS, 0.05 μg/μl proteinase K)
and incubated overnight at 56°C. The DNA solution was centrifuged
for 15 min at 9600× g after adding the one-fourth volume of saturated
NaCl. The supernatant was transferred to a new tube and the DNAre fusion junctionb 
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Figure 1. Telomere fusions arise prior to KRAS/TP53 mutations and
are retained during tumor progression. (A) Dot blots show represen-
tative telomere fusion assays. Each case contains six PCR reactions
using TAR-fusion PCR primers and two PCR reactions using control
primers. Telomere fusion junctions were PCR-amplified, denatured
and dot-blotted onto membranes and hybridized to a DIG-labeled
telomere probe. (B) Relationship between telomere fusion status and
lymph node invasiveness. N0, lymph node non-invasive case. N1–2,
lymph node invasive case. The data from tumor tissue samples
represent only “neogenetic” fusion. (C) Relationship between telo-
mere fusion status andmutation status inKRAS/BRAF and TP53genes.
Student's t test was performed in (B) and (C).
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rinse with 70% ethanol, DNA was resolved in TE. The DNA
concentration was measured by Nanodrop 2000 spectrophotometer
(Thermo Fisher Scientific).
Telomere Quantitative PCR (qPCR) Assay
Telomere length was determined using real-time qPCR [52,53]
with minor modifications. All real-time PCR reactions were carried
out using the LightCycler 480 (Roche Diagnostics) and Roche-brand
SYBR green I master mix. Commercialized diploid DNA was used as
a control template (Promega). Telomere and reference sequences were
amplified using the following conditions: 95°C for 10 minutes to
activate DNA polymerase, and 2 cycles each at 95°C for 10 seconds,
49°C for 10 seconds, and then 35 cycles each at 95°C for 10 seconds,
60°C for 10 seconds and 72°C for 10 seconds. LightCycler 480software version 1.5 was used for analysis. Primer sequence
information is shown in Table 2. The reference primers minimized
the effect of chromosome and/or gene copy number variation in each
sample by amplifying 13 loci on eleven chromosomes including
chromosome 1, 4, 5, 6, 7, 8, 12, 13, 19, 21, and X.
Telomeric Repeat Amplification Protocol (TRAP) Assay
Telomerase activity was analyzed by TRAP assay as previously
described [54]. Briefly, 1 μg of protein extracts was used for the assay
in 50 μl reactions with Taq DNA polymerase. The PCR products
were electrophoresed in a 12.5% non-denaturing polyacrylamide gel
and stained with SYBR Gold dye (Life Technologies). The gels were
scanned using the STORM 860 molecular imager and quantified
using ImageQuant TL software (GE Healthcare Life Sciences).
Signals from all telomerase ladders were summed for a net TRAP
activity per sample. The data were normalized to the signal from the
internal standard (IC), and then % was calculated as relative to the
HeLa TRAP standard (Figure 2B; [55]). TRAP activity of 1.0 μg
HeLa extract is defined as 100%.
Telomere Associated Repeat (TAR)–Fusion PCR Assay
Telomere fusions were determined using TAR-fusion PCR assay
[50] with minor modifications. Two-step touchdown PCR was
performed in a 20 μl reaction mixture using 50 ng of DNA, multiple
primers, 10% 7-Deaza-dGTP (Roche Diagnostics), and Advantage
GC Genomic LA Polymerase Mix (Clontech Laboratories). Multiple
PCR primers were designed within TAR1 (Telomere Associated
Repeat 1)–like sequences common to many chromosomes distal
regions [56]. The primer sequence information and PCR condition
are shown in Tanaka et al. [50]. As an internal positive PCR control,
the following primers were used for amplifying ancestral interstitial
telomere head-to-head fusion within chromosome 2q13-q14.1 [57]:
5′-GCA AGG CGA GGG GCT GCA TTG CAG GGT GAG-3′,
5′-CAG CAGGGGGCGCTGGAC AGC ACTGTA AG-3′. TAR
fusion PCR products were dot-blotted onto Hybond+ membranes
and hybridized using a DIG-labeled telomere probe (Roche
Diagnostics). Six PCR reactions per each case were used for every
PCR. Telomere fusion was defined as ‘negative’ when TAR-fusion
PCR did not amplify any products using total twenty PCR reactions
which correspond to more than 1 × 105 cells.
Analysis of Telomere Fusion Junctions
TAR-fusion PCR products were purified by the GENECLEAN
Turbo Kit (MP Biomedicals). Cloning and transformation were carried
out with a TOPO TA PCR Cloning Kit (Life Technologies). TOP10
(Life Technologies) or SURE (Agilent Technologies) competent cells
were used for transformation with blue/white selection. White colonies
were picked and each inserted DNA was confirmed by colony PCR.
More than 1 kb of inserted DNA length was selected for DNA
sequencing. The sequencing service was provided by GENEWIZ after
DNA isolation using Qiaprep Miniprep kit (Qiagen). Sequence
alignments were performed using the University of California Santa
Clara Genome Bioinformatics database (http://genome.ucsc.edu/).
Gene Mutation Analysis
TP53 mutation between exons 5 and 8, KRAS mutation at codons
12, 13 and 61, as well as BRAF mutation (V600E) at exon 15 were
determined by direct sequencing. The sequencing service was
provided by GENEWIZ after PCR. The primer sequence
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Figure 2. Colon cancer develops with increasing telomere shortening. (A) Influence of DNA ploidy in the existing PCR method developed
by Cawthon [52,53]. Graph shows a poor correlation between two different reference primers, 36B4 and β-globin [52]. X-axis represents
36B4 primers, which encodes acidic ribosomal phosphoprotein PO and y-axis represents β-globin primers. Human diploid DNA was used
as reference template (36B4:β-globin = 1:1 ratio) and relative value in each case was calculated based on the value from diploid DNA.
Each circle shows human diploid DNA in black, tumor tissue DNA in gray, and adjacent tissue DNA in white, respectively. Dash line
indicates ±10% far from the 1:1 ratio. (B) Semi-logarithmic graph shows a linear correlation between input DNA from all specimens and
Cp (crossing-point) value of new reference primers for improved telomere qPCR assay. The Cp is the cycle number at which the
fluorescence rises appreciably above the background fluorescence. Eighteen pairs of matched tumor and adjacent tissue DNA were
amplified, along with diploid DNA. (C) Change in telomere length was measured in tumor DNA compared to the matched adjacent DNA.
Change in b1 represents telomere shortening in tumor DNA. Graph shows significant regression of telomere length in lymph node
invasive-positive group (N = 8, average = 0.526) compared to lymph node invasive-negative group (N = 10, average = 0.742). Black bar
represents average in each group. (D) Relationship between telomere fusion status and change in telomere length. Black bar represents
average in each group. Paired Student's t test was performed.
818 Telomere fusion in colon cancer Tanaka et al. Neoplasia Vol. 16, No. 10, 2014information is shown in Table 1. A summary of the sequence analysis
was shown in Table 3.
Statistical Analysis
All statistical analyses were performed using Pearson correlation,
Fisher's exact test, and the two-tailed Student t test. A P value of less
than .05 was considered statistically significant.
Results and Discussion
Relationship Between Telomere Fusion Status and Known
Genetic Changes in Colon Carcinogenesis
Determining the presence of telomere fusion is the firmest
evidence that telomeres are actually dysfunctional in cells. Molecular
analyses of telomere fusion in human epithelial tissue have begun
since two groups have independently developed PCR-based methods
to amplified telomere fusion junctions ([50,58]). Although Rogeret al. reported that telomere fusion events were detected in 6 of 45
adenomatous colorectal polyps (13.3%) and 5 of 8 colorectal
adenocarcinomas (62.5%), there was little discussion about the
temporal sequence of telomere dysfunctions along with any other
factors which may be related to the telomere fusion events [38]. In
this study, we further investigated both the degree and nature of
telomere dysfunctions in 18 paired tissue samples of tumor and adjacent
tissue lesions from sporadic colon cancer patients. Informative
characteristics of all specimens were shown in Table 1. Eight cases
belonged to a lymph node invasive cancer group and the remaining 10
cases were a non-invasive cancer group. Because cancer cells are almost
always intermixed with an unknown fraction of normal cells, we
selected specimens with more than 50% of tumor cells and repeated
experiments with multiple reactions. The TAR-fusion PCR assay is
composed of two steps, multiplex PCR and dot-blot using a telomere
probe.We improved the current assay by using internal control primers
to rule out the possibility of false negative amplification (Figure 1A).
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Figure 3. Telomerase activity is up-regulated in tumor tissue compared to the matched adjacent tissue and the up-regulation is associated
with the presence of genemutations. (A) Representative TRAP result was shown. HeLa cell extract (1 μg, 0.1 μg, and 0.01 μg) was used as
a positive control. N represents no template (lysis buffer) as a negative control. IC represents internal control for PCR. A and T represent
adjacent and tumor tissue, respectively. Two individual gels were combined in this image. (B) Double-logarithmic graph shows standard
curve for calculating percent of HeLa's TRAP activity. The progression line closely fits the data (R2 = 0.971). Data represent mean ± SEM
(N = 6). (C) Semi-logarithmic graph shows that tumor tissues have higher TRAP activity than their adjacent tissues TRAP in all 18 cases.
More than 20% (corresponding to 0.05–0.06 μg of HeLa extract) of TRAP activity was defined as higher. Dashed line represents 20%
TRAP activity. (D) Histogram shows higher telomerase activity is significantly associated with the presence of mutations in TP53 and/or
either KRAS or BRAF genes. (E) Relationship between telomere fusion status and TRAP activity. Black bar represents average in each
group. Paired Student's t test was performed.
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only in cancer tissues but also in five adjacent non-cancerous tissues
(e.g., case #808-41; Figure 1, A and B, and Table 3). This result
reinforced previous evidence that pathologically normal did not always
mean genetically normal [59–63]. Therefore, we carefully estimated the
presence of ‘neogenetic’ telomere fusion in each cancer group by
excluding identical fusions between adjacent non-cancerous tissue and
the matched cancer specimen based on the fusion junction DNA
sequences (see below). While we do not understand at this point how
cancer tissue contains the same fusion type as the adjacent tissue, it could
be due to the fact that identical fusions resulted simply from intermixed
tissues or cancer tissue evolved from a cell in the adjacent tissue.
Overall, telomere fusions were highly detectable in 61.1% of total
cases independently of the lymph node invasion status (Figure 1B).
Telomere fusions are presented in 60% of the cases without any
hotspot mutations in TP53, KRAS, and BRAF genes, as well as
77.8% of the cases with TP53 and/or KRAS mutation(s) (Figure 1C).
These results suggest that telomere fusions arise prior to the occurrenceof oncogenic/tumor suppressor mutations and are retained during a
mutagenic period. In contrast, BRAF V600E mutation alone was
poorly associated with the presence of telomere fusion in colon cancer
(Figure 1C). This observation is consistent with the previous findings
that BRAF V600E mutation is a reasonable indicator of CIN-negative
colorectal cancer [34]. Therefore, it is speculated that cancer with a
BRAF V600E mutation alone may not be involved in the telomere
dysfunction-driven genomic instability pathway.
Change in Telomere Length Between Lymph Node Invasive
and non-Invasive Colon Cancer
The current telomere qPCR method facilitates measurement of
relative telomere length in large cohorts, especially in the scope of
estimating cancer risk, mortality, or natural survival rate by using
peripheral leukocyte telomere length [52,53]. This method is designed
to determine average telomere length normalized by a single copy gene
such as human β-globin gene. Hence, this method is optimized for
diploid DNA samples as a template. As expected, DNA from tumor
GAGCTCCGTT TTCCTCTGCA GAGACTTCGG GGGGAACGCG ATGACGGAGC TGCATTCTGC TCAGCACAGA CGCGGGAGAC ATCGCGAAGG 
TGGAGCAGCG CATGCCTCTC CACAGACGTT GGGGGCACTG CTTCATTTTG GGACAACTGG GGGCCACATC CACGGTAAAG ATCCTTCCTC 
TTTGCAGCCG AGAATAATGG GGGTTGGGGT TAGGGTTAGG GTTAGGGTTA GGGTTTAGGG TGAGGGTGAG GGTGAGGGTG AGGGTGAGGG
TGAGGGTTAG GGCGAGGGCT AGGGCTAGGG CTAGGGCTGG GGCTAGGGCT GGGGTTAGGG TTAGGGGTTA GGGTGAGGGT GAGGGTGAGG
GTGAGGGTGA GGGTTAGGGT TAGGGTTAGG GTTAGGGTAG GGTTAGGGTT AGGGTTAGGG TTAGGGGTCG GGGTCGGGAA AGAAGAAACT 
CGGAACACAT CTGAACATCA GAAGAAACAA ACTCCGGACA TGCCACCTTT AAGAACTGTA ACACTCACCG CGAGGTTCCG CGTCTTCATT 
CTTGAAGTCA GTGAGACCAA GAACCCACCA ATTCCAGACA CACTAGGACC CTGAGACAAC CCCTAGAGGA GCACCTGGTC GATAACCCAG 
TTCCCATCTG GGATTTAGGG GACCTGGACA GCCCGGAAAA TGAGCTCCTC ATCTCTAACC CAGTTCCCCT GTGGGGATTT AGGGGACCAG 
GGACAGCCCG TTACATCAGC CCCTGGTCTC TAACCCAGTT CCCTTCTGGA ATTTAGGGGC CCTGGGACAG CCCTGTACAT GAGCTCCTGG 
TCTGTAACAC AGTTC
4p_tel or 4q_tel
Xp_tel or Yp_tel
B
Tumor 
N=18
Fusion (+)
N=15
Fusion (-)
N=3
Indistinguishable
N=4
Neogenetic
N=11
GCTTTGACAC GACTCGGGGC TTCATTGATG GTGAATACAA TCCTTTCTGT TTGCAGCGCT GAATATTCAG GGTCAGAGAA CAGTTAGAAG 
GGTTCAGTGT GGAAAACGGG AAATCAAAAG CCCCTCTGAA TCCTGCGCAC CGAGATTCTC CCCAGCCAAG GTGAGGCGGC AGCAGTGGGA 
GATCCACACC GTAGCGTTGG AACACAAATG CAGCATTACA AATGCAGACA TGACACCGAA AATATAACAC ACCCCATTGC TCATGTAACA 
AGCACCTGTA ATGCTAATGC ACTGCCTCAA AACAAAATAT TAATATAAGA TCGGCAATCT GCACACTGCC GTGCAGTGCT AAGACAGCAA 
TGAAAATAGT CAACATAATA ACCCTAATAG TGTTAGGGTT AGGGTGAGGG TGAGGGTGAG GGTGAGGGTG AGGGTTGGGT GAGGGTGAGG
GTGAGGGTGA GGGTGAGGGT CAGGGTGAGG GCTGAGGGTC AGGGCGAGGG CTAGGGTCAG GGCTAGGGCT AGGGGTCAGG GCCAGGGCTA
GGGTCAGGGT CAGGGTCAGG GTCAGGGTCA GGGTTAGGGG TTAGGGTCAG GGTCAGGGTC AGGGTCAGGG TCAGGGTTAG GGGTCGGGGT
CAGGGTTAGG GTTAGGGTTA GGGTCAGGGT TAGGGGTCAG GGTCAGGGTC AGGGTCAGGG TCAGGGTCAG GGTTAGGGGT TAGGGTTAGG
GTTAGGGTTA GGGTTAGGGT GAGGGTGAGG GTGAGGGTGA GGGTCAGGGT GAGGGCTGAG GGTCAGGGCG AGGGCTAGGG GTCAGGGCTA
GGGCTAGGGG TCAGGGCTAG GGCTAGGGTC AGGGTCAGGG TCAGGGTCAG GGTGGGCAGA ACGCCGCTCC AACCTCGCGG AGCCCCCGTC 
CCACCCAACC GCCCGCGTCT GTGCTGAGGA GAATGCTGCT TCGCCTCCGC GGTACCCCAA AAGGCTGTGC AAAAGAGAAC GCAACTCCGC 
CCTCGCAAAG GC
7q_tel or 12q_tel
7q_tel or 12q_tel
A
C D
Fusion Type N
A 5
B 1
A & B 2
Other 3
11
Figure 4. The nature of telomere fusion junctions may be linked to neoplasticity. (A and B) Representative DNA sequences of telomere
fusion junctions in tumor DNA. (A) shows the sequences between 7q or 12q and 7q or 12q. (B) shows the sequences between 4p or 4q
and Xp or Yp. Telomeric repeats were underscored. Microhomology at each fusion junction was indicated by boldface. (C) Each tumor
was categorized by telomere fusion type. A and B correspond to the telomere fusion junction shown in (A) and (B), respectively.
(D) Frequency of telomere fusion in tumor tissues.
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amplification between two different single copy genes (Figure 2A;
β-globin and 36B4). This finding coincides evidence that cancer-driven
DNA is no longer diploid [64–66]. Interestingly, there is no 1:1
correlation even in DNA from some of surrounding non-cancerous
tissue samples, supporting previous evidence that those tissues contain
aneuploid DNA [67,68]. Indeed, several studies have demonstrated
that surrounding tissues no longer act normal in terms of gene
expression and genetic mutation [59–63]. Therefore, to avoid the
negative impact on changes in chromosome and/or gene copy number
in each sample, we optimized the telomere qPCR by using new
designed reference primers (Table 2). A significant correlation as 0.827
of coefficient of determination (R2) was shown in a relationship
between reference Cp value and template DNA amount in each sample
(Figure 2B). The 18 paired tumor and adjacent tissue specimens were
used for the telomere length measurement. The alteration of average
telomere length in tumor tissues was evaluated by comparison of their
adjacent non-cancerous tissues. The results revealed that the change in
telomere length was affected by a degree of regional lymph node
involvement (P = .007, Figure 2C). Consistent with other cancer studies
[69–71], our findings suggested that colon cancer could develop with
continuing telomere shortening. However, there have been observa-
tions indicating that telomere length is not correlated with tumor stage
or grade in colorectal cancer [35,37,72]. These contradictions couldresult from interpretation without sufficient information about the
purity of specimens, family history of cancer, or additional therapies
besides surgery, because we now know that these factors have an impact
on telomere length alteration and need to have been fully considered
[73–77]. Also, some of the analyses were performed by comparing
average telomere length in each group, instead of comparing age-
adjusted telomere length or a ratio of telomere length in cancer tissue to
corresponding non-cancer tissue in each patient. This is critical to adjust
the age-dependent variation of telomere length values [78,79].
Establishing a standardized analysis technique may help resolve the
different interpretations of telomere lengthmeasurement. Furthermore,
there was no significant association between telomere length and
telomere fusion in this study (P N .05, Figure 2D). It is notable that
telomere fusion was detected even in carcinoma in situ (e.g., case
#1012-35, Table 3). This observation is not ruled out of a causal
connection between telomere shortening and telomere fusion, however
instead, indicates that the sensitivity of TAR-fusion PCR as a telomere
dysfunction marker could be higher than both telomere qPCR and
TRAP assay (Figures 2D and 3D, also see below).
Timing of the Onset of Telomerase up-Regulation in Colon Cancer
We next quantified telomerase activity carefully in each sample
using TRAP assay (Figure 3A). After subtracting a PCR internal
control (IC) signal from the intensity of net telomerase ladders,
Neoplasia Vol. 16, No. 10, 2014 Telomere fusion in colon cancer Tanaka et al. 821telomerase activity was shown as a percentage (%) after normalization
to the telomerase activity in HeLa cells. We confirmed that there was
a linear correlation between TRAP activity and the amount of HeLa
protein in a log-log plot (R2 = 0.971, Figure 3B). In all 18 cases, we
observed increasing telomerase activity independent of the degree of
regional lymph node involvement (Figure 3C). Interestingly, when
samples were divided into two groups with or without hotspot
mutation(s) in TP53 and/or either KRAS or BRAF genes, 83.3% of
the mutation-positive group has higher (b20%) telomerase activity
(Figure 3D). In contrast, only 16.7% of the mutation-negative group
has higher telomerase activity. This result suggested that the up-
regulation of telomerase activity was associated with the presence of
known genetic changes, and corroborated an existing idea that the full
activation of telomerase could be a late event in colorectal
carcinogenesis [80–83]. No link between telomerase activity and
telomere length was observed in this study (data not shown). An
association between telomere fusion rate and telomerase activity was
not statistically significant (Figure 3E).
The Nature of Telomere Fusion Junctions
To identify the key internal structures of telomere fusion junctions,
we performed the sequence analysis. The results showed that all fusion
junctions lost telomeric (TTAGGG)n (or telomere-like) sequences on
one end and fused to the most proximal subtelomere region of another
chromosome. We identified two major fusion junction sequences in
sporadic colon cancer specimens (Figure 4,A andB). Out of 11 telomere
fusion-positive cancers, seven cancers had 7q to 7q (or 12q to 12q, or 7q
to 12q) fusion junction (Figure 4C and Table 3). Interestingly, these two
junctions are different from those that were found previously in chronic
lymphocytic leukemia and breast cancer [50,70], proposing that the
chromosomes involved in end-to-end fusions may not be randomly
distributed. In other words, the telomere fusion may occur preferentially
between cancer types. It is expected that identifying the target of specific
chromosomes or elements responsible toward malignancy could
potentially provide useful clues into targeting treatment strategies, as
well as into screening cancer risk. Our result does not necessarily imply
that only chromosome 7 and 12 are vulnerable to fusion in sporadic
colon cancer, in part because our PCR primers do not cover all possible
fusion types. Total 15 out of 18 cases contained telomere fusion,
however, telomere fusion was observed even in tissue adjacent to
cancerous lesions in five cases. Four of themwere indistinguishable from
telomere fusion found in their cancer tissues (Figure 4D and Table 3).
Conclusions
This careful correlative study using paired tumor and adjacent tissue
specimens corroborated the concept that telomere fusion is indeed
present in the early stages of sporadic colon cancer, prior to TP53
and/or KRAS mutations, critical shortening of mean telomere length,
and telomerase activation in human colon cancer. In addition, the type
of telomere fusionmay vary with the type of cancer. Our results pave the
way for further investigations to help elucidate the relationship between
telomere dysfunction dynamics and human carcinogenesis. Moreover,
new insights gained from each normal adjacent tissue will facilitate our
further understanding that how the neighboring cells impinge on non-
autonomous tumor progression.
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